Pascal and Francis Bibliographic Databases

Help

Search results

Your search

au.\*:("SUPKO, Jeffrey G")

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 38

  • Page / 2

Export

Selection :

  • and

Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecinsGARCIA-CARBONERO, Rocio; SUPKO, Jeffrey G.Clinical cancer research. 2002, Vol 8, Num 3, pp 641-661, issn 1078-0432Article

Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogsSUPKO, Jeffrey G; GARCIA-CARBONERO, Rocio; PUCHALSKI, Thomas A et al.Cancer chemotherapy and pharmacology. 2001, Vol 48, Num 3, pp 202-208, issn 0344-5704Article

Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancerMEYERHARDT, Jeffrey A; CLARK, Jeffrey W; RYAN, David P et al.Cancer chemotherapy and pharmacology. 2007, Vol 60, Num 5, pp 661-670, issn 0344-5704, 10 p.Article

Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumorsSUPKO, Jeffrey G; EDER, Joseph P; RYAN, David P et al.Clinical cancer research. 2003, Vol 9, Num 14, pp 5178-5186, issn 1078-0432, 9 p.Article

A phase II study of weekly Paclitaxel in elderly patients with advanced non-small cell lung cancerFIDIAS, Panos; SUPKO, Jeffrey G; SKARIN, Arthur et al.Clinical cancer research. 2001, Vol 7, Num 12, pp 3942-3949, issn 1078-0432Article

A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2HOLKOVA, Beata; SUPKO, Jeffrey G; KMIECIAK, Maciej et al.Clinical cancer research (Print). 2013, Vol 19, Num 7, pp 1873-1883, issn 1078-0432, 11 p.Article

A woman with a mass in the pelvisKRASNER, Carolyn N; ROCHE, Maria; HOROWITZ, Neil S et al.The New England journal of medicine. 2006, Vol 354, Num 15, pp 1615-1625, issn 0028-4793, 11 p.Article

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcomaLAVERDIERE, Caroline; KOLB, E. Anders; GOORIN, Allen M et al.Cancer. 2003, Vol 98, Num 4, pp 832-840, issn 0008-543X, 9 p.Article

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated dailyEDER, Joseph P; SUPKO, Jeffrey G; CONNORS, Susan et al.Journal of clinical oncology. 2002, Vol 20, Num 18, pp 3772-3784, issn 0732-183X, SUPArticle

A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumorsPENSON, Richard T; SUPKO, Jeffrey G; SEIDEN, Michael V et al.Cancer. 2001, Vol 92, Num 5, pp 1156-1167, issn 0008-543XConference Paper

Metabolic Inhibition of Galectin-1-Binding Carbohydrates Accentuates Antitumor ImmunityCEDENO-LAURENT, Filiberto; OPPERMAN, Matthew J; MURPHY, George F et al.Journal of investigative dermatology. 2012, Vol 132, Num 2, pp 410-420, issn 0022-202X, 11 p.Article

Identification of the in Vitro Metabolites of 3,4-Dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (ARQ 501; β-Lapachone) in Whole BloodMIAO, Xiu-Sheng; PENGFEI SONG; XIAOYING HE et al.Drug metabolism and disposition. 2008, Vol 36, Num 4, pp 641-648, issn 0090-9556, 8 p.Article

Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndromeSROUJI, Serene S; PAGAN, Yanira L; D'AMATO, Fernando et al.The Journal of clinical endocrinology and metabolism. 2007, Vol 92, Num 4, pp 1347-1352, issn 0021-972X, 6 p.Article

Phase i clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumorsBERKENBLIT, Anna; EDER, Joseph P; RYAN, David P et al.Clinical cancer research. 2007, Vol 13, Num 2, pp 584-590, issn 1078-0432, 7 p., 1Article

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumorsRYAN, David P; APPLEMAN, Leonard J; CUSACK, James et al.Cancer. 2006, Vol 107, Num 10, pp 2482-2489, issn 0008-543X, 8 p.Article

Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignanciesRYAN, David P; SUPKO, Jeffrey G; EDER, J. Paul et al.Clinical cancer research. 2001, Vol 7, Num 2, pp 231-242, issn 1078-0432Article

Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignanciesBUNNELL, Craig A; SUPKO, Jeffrey G; EDER, Joseph Paul et al.Cancer chemotherapy and pharmacology. 2001, Vol 48, Num 5, pp 347-355, issn 0344-5704Article

Exposure to phytoestrogens in the perinatal period affects androgen secretion by testicular leydig cells in the adult ratAKINGBEMI, Benson T; BRADEN, Tim D; KEMPPAINEN, Barbara W et al.Endocrinology (Philadelphia). 2007, Vol 148, Num 9, pp 4475-4488, issn 0013-7227, 14 p.Article

Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumorsEDER, Joseph P; RYAN, David P; SUPKO, Jeffrey G et al.Cancer chemotherapy and pharmacology. 2006, Vol 58, Num 1, pp 107-116, issn 0344-5704, 10 p.Article

A phase I study of bortezomib plus irinotecan in patients with advanced solid tumorsRYAN, David P; O'NEIL, Bert H; EDER, Joseph P et al.Cancer. 2006, Vol 107, Num 11, pp 2688-2697, issn 0008-543X, 10 p.Article

Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: Potentiation by Cox-2 inhibitionMERCHAN, Jaime R; JAYARAM, Deepa R; SUPKO, Jeffrey G et al.International journal of cancer. 2005, Vol 113, Num 3, pp 490-498, issn 0020-7136, 9 p.Article

A Phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumorsSEIDEN, Michael V; NG, Shu-Wing; SUPKO, Jeffrey G et al.Clinical cancer research. 2002, Vol 8, Num 3, pp 691-697, issn 1078-0432Article

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicityPUCHALSKI, Thomas A; RYAN, David P; GUZMAN, Cecilia et al.Cancer chemotherapy and pharmacology. 2002, Vol 50, Num 4, pp 309-319, issn 0344-5704, 11 p.Article

Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous LeukemiaATTAR, Eyal C; DEANGELO, Daniel J; LEVINE, James et al.Clinical cancer research. 2008, Vol 14, Num 5, pp 1446-1454, issn 1078-0432, 9 p.Article

The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochlorideGROSSMAN, Stuart A; CARSON, Kathryn A; BATCHELOR, Tracy T et al.Clinical cancer research. 2006, Vol 12, Num 17, pp 5174-5181, issn 1078-0432, 8 p.Article

  • Page / 2